Delhi High Court grants interim; restrains sale of Corex syrup

Sale of over 300 drugs' combination have been banned; HC granted relief saying they've been in business for 25 years

The Delhi High Court today granted interim stay of notification restraining sale of pharma major Pfizer's cough syrup 'Corex' and directed the government not to take coercive steps against the company.

Justice Rajiv Sahai Endlaw granted the interim relief to the company saying it has been selling the cough syrup for the last 25 years.

Read more from our special coverage on "PFIZER"

• Pfizer dips after ban on Corex cough syrup in India
• Pfizer stops selling popular Corex cough syrup in India after ban
• Pfizer to get patent for cholesterol lowering formulation

The court also issued notice to the Health ministry directing it to file status report after taking instruction on what was the finding of the expert committee set up by it following which sale of over 300 drugs' combination have been banned across India with effect from March 10.

"List on Monday. Till then the effect of notification by the petitioner shall remain stayed. No coercive steps till then," the court said.

The court's order came on a plea moved by Pfizer who contended that no show cause notice or hearing was granted prior to the notification.